drugset
drugset / Trial / NCT01066611

Study to Investigate Effects of CAL-263 in Subjects With Allergic Rhinitis Exposed to Allergen in an Environmental Chamber

NCT01066611 ↗

Phase 1 Completed 48 enrolled Gilead Sciences
RandomizedCrossoverQuadruple-blindTreatment

Summary

The purpose of this study is to determine the safety and effect of CAL-263 in subjects with allergic rhinitis.

Timeline

Start
2010-01
Primary completion
2010-04
Completion
2010-04

Drugs

EvaluationDrugModalityDoseRoute
Comparator CAL-263 Unknown 10 mg Oral

Indications

allergic rhinitis